Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2001 pp 23–71Cite as

Neue Arzneimittel

  • Chapter

  • 68 Accesses

Zusammenfassung

Die Verordnungen neuer Arzneimittel haben in den vergangenen Jahren überdurchschnittlich stark zugenommen. Hauptgrund für diese Entwicklung dürfte der stetige Aufwärtstrend der neuen Wirkstoffe sein, die jährlich in Deutschland auf den Markt kommen (Abbildung 2.1). Die zunehmende therapeutische Bedeutung der Neueinführungen hat uns dazu veranlaßt, die neuen Wirkstoffe des Jahres 2000 und ihre Verordnungsentwicklung ausführlicher zu besprechen und in einem eigenen Kapitel darzustellen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Al-Salman J., Arjomand H., Kemp D.G., Mittal M. (2000): Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann. Intern. Med. 132: 121–124.

    PubMed  CAS  Google Scholar 

  • American Thoracic Society (2000): Guidelines for methacholine and exercise challenge testing - 1999. Am. J. Respir. Crit. Care Med. 161: 309–329.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2000): Vorsicht bei der Verordnung von Bupropion zur Raucherentwöhnung. Dtsch. Ärztebl. 97: A–863.

    Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2000): Etanercept (Enbrel®): Demyelisierung des ZNS. Pharm. Ztg. 145: 3786.

    Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2001): Levacetylmethadol (Orlaam®). Pharm. Ztg. 146: 1367.

    Google Scholar 

  • Banderali G., Riva E., Fiocchi A., Cordaro C.I., Giovannini M. (1995): Efficacy and to-lerability of levodropropizine and dropropizine in children with non-productive cough. J. Int. Med. Res. 23:175–183.

    PubMed  CAS  Google Scholar 

  • Bariffi F., Tranfa C., Vatrella A., Ponticiello A. (1992): Protective effect of levodropropizine against cough induced by inhalation of nebulized distilled water in patients with obstructive lung disease. Drugs Exp. Clin. Res. 18:113–118.

    PubMed  CAS  Google Scholar 

  • Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C. et al. (2000): A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586–1593.

    Article  PubMed  CAS  Google Scholar 

  • Birnstiel S., Wulfert E., Beck S.G. (1997): Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn-Schmiedebergs Arch. Phamacol. 356: 611–618.

    Article  CAS  Google Scholar 

  • Bleyer A.J., Burke S.K., Dillon M., Garrett B., Kant K.S., Lynch D. et al. (1999): A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 33: 694–701.

    Article  PubMed  CAS  Google Scholar 

  • Bolli G.B., Owens D.R. (2000): Insulin glargine. Lancet 356:443–445.

    Article  PubMed  CAS  Google Scholar 

  • Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B. et al. for the VIGOR Study Group (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  • Brusilow S.W., Maestri N.E. (1996): Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv. Pediatr. 43:127–170.

    PubMed  CAS  Google Scholar 

  • Burstein H.J., Kuter I., Richardson P.G. et al. (2000): Herceptin and vinorelbine for HER2-positive metastatic breast cancer: a phase II study. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 2000: 392a.

    Google Scholar 

  • Catena E., Daffonchio L. (1997): Efficacy and tolerability of levodropropizine in adult patients with non-productive cough. Comparison with dextromethorphan. Pulm. Pharmacol. Ther. 10: 89–96.

    Article  PubMed  CAS  Google Scholar 

  • Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., Leppik I. (2000): Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236–242.

    Article  PubMed  CAS  Google Scholar 

  • Chan C.-C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D. et al. (1999): Rofecoxib [Vioxx, MK-0966; 4-(4’-Methylsulfonylphenyl)-3-phenyl-2-(5H)-fu-ranone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.J. Pharmacol. Exp. Ther. 290: 551–560.

    PubMed  CAS  Google Scholar 

  • Clemett D., Goa K.L. (2000): Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59: 957–980.

    Article  PubMed  CAS  Google Scholar 

  • Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L. et al. (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639–2648.

    PubMed  CAS  Google Scholar 

  • Crandall C. (2001): Risedronate. A clinical review. Arch Intern. Med. 161: 353–360.

    Article  CAS  Google Scholar 

  • Croxatto H.B., Makarainen L. (1998): The pharmacodynamics and efficacy of Im-planon. An overview of the data. Contraception 58 (Suppl. 6): 91S–97S.

    Article  PubMed  CAS  Google Scholar 

  • Croxatto H.B., Urbancsek J., Massai R., Bennink H.C., van Beek A. and the Implanon® Study Group (1999): A multicentre efficacy and safety study of the single contraceptive implant Implanon®. Hum. Reprod. 14: 976–981.

    Article  PubMed  CAS  Google Scholar 

  • De la Garza R., Johanson C.E. (1987): Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys. J. Pharmacol. Exp. Ther. 243: 955–962.

    PubMed  Google Scholar 

  • Dobson R. (2001): Antismoking drug comes under scrutiny after deaths. Brit. Med. J. 322: 452.

    Article  PubMed  CAS  Google Scholar 

  • Dooley M., Plosker G.L. (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871–893.

    Article  PubMed  CAS  Google Scholar 

  • Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., Schneider R.L. for the Piaglitazone 027 Study Group (2000): Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin. Ther. 22:1395–1409.

    Article  PubMed  CAS  Google Scholar 

  • Emery P., Zeidler H., Kvien T.K., Guslandi M., Naudin R., Stead H. et al. (1999): Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354:2106–2111.

    Article  PubMed  CAS  Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (1999): Regranex, European Public Assessment Report (EPAR), 29 March 1999.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000a): Trac-tocile, European Public Assessment Report (EPAR), 20 January 2000.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000b): Enbrel, European Public Assessment Report (EPAR), 3 February 2000.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000c): EMEA public statement on etanercept (Enbrel) - serious hematological reactions -, The European Agency for the Evaluation of Medicinal Products, 3 October 2000.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000d): Draft concept paper on the development of a CPMP points to consider document on the non-clinical assessment of the carcinogenic potential of human insulin analogues. 12 April 2000.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000e): Avandia, European Public Assessment Report (EPAR), 11 July 2000.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2000f): Renagel, European Public Assessment Report (EPAR), 28 January 2000.

    Google Scholar 

  • Feldman A.M., Lorell B.H., Reis S.E. (2000): Trastuzumab in the treatment of meta-static breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102: 272–274.

    Article  PubMed  CAS  Google Scholar 

  • Foidart J.-M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. (2000): A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reproduct. Health Care 5:124–134.

    Article  CAS  Google Scholar 

  • Fonseca V., Rosenstock J., Patwardhan R., Salzman A. (2000): Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283:1695–1702.

    Article  PubMed  CAS  Google Scholar 

  • Forman L.M., Simmons D.A., Diamond R.H. (2000): Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132:118–121.

    PubMed  CAS  Google Scholar 

  • Fornier M., Esteva F.J., Seidman A.D. (2000): Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer. Semin. Oncol. 27 (Suppl. 11): 38–45.

    PubMed  CAS  Google Scholar 

  • Fricke U. (2000): Neue Arzneimittel - Ein Überblick. Therapiesymposium 2000. Arzneimittelkommission der deutschen Ärzteschaft, Frankfurt am Main.

    Google Scholar 

  • Friedrich J.M., Sergeev P.V., Shimanovskii K.L. (1995): Vergleichende Untersuchung zur Freisetzung von Histamin aus basophilen humanen Granulozyten bei ionischen und nicht-ionischen Kontrastmitteln. Radiologe 35: S24.

    Google Scholar 

  • Gajwani P., Pozuelo L., Tesar G.E. (2000): QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 41: 63–65.

    Article  PubMed  CAS  Google Scholar 

  • Gale E.A.M. (2001): Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875.

    Article  PubMed  CAS  Google Scholar 

  • Gillies P.S., Figgitt D.P., Lamb H.M. (2000): Insulin glargine. Drugs 59: 253–260.

    Article  PubMed  CAS  Google Scholar 

  • Glue P., Fang J.W., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K. et al. for the Hepatitis C Intervention Therapy Group (2000a): Pegylyated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68: 556–567.

    Article  PubMed  CAS  Google Scholar 

  • Glue P., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M. et al. for the Hepatitis C Intervention Therapy Group (2000b): A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 32: 647–653.

    Article  PubMed  CAS  Google Scholar 

  • Goss P.E., Strasser K. (2001): Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 19: 881–894.

    PubMed  CAS  Google Scholar 

  • Grant S.M., Faulds D. (1992): Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43: 873–888.

    Article  PubMed  CAS  Google Scholar 

  • Harrison C. (2001): Bupropion for smokers. Bupropion may not be as good as editorial implies. Brit. Med. J. 322: 431.

    Article  PubMed  CAS  Google Scholar 

  • Hassan-Alin M., Andersson T., Bredberg E., Röhss K. (2000): Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur. J. Clin. Pharmacol. 56: 665–670.

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L., Linkeschova R., Rave K., Hompesch B., Sedlak M., Heise T. (2000): Time-action profile of the long-actinig insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23: 644–649.

    Article  PubMed  CAS  Google Scholar 

  • Horton J. (2001): HER2 and trastuzumab in breast cancer. Cancer Control 8: 103–110.

    PubMed  CAS  Google Scholar 

  • Jackson L.M., Hawkey C.J. (2000): COX-2 selective nonsteroidal anti-inflammatory drugs. Do they really offer any advantages? Drugs 59:1207–1216.

    Article  PubMed  CAS  Google Scholar 

  • Jauch A., Fsadni M., Gamba G. (1999): Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefe’s Arch. Clin. Exp. Ophthalmol. 237: 705–713.

    Article  CAS  Google Scholar 

  • Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R. et al. (1999): A controlled trial of sustained-release Bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 340: 685–691.

    Article  CAS  Google Scholar 

  • Kahrilas P.J., Falk G.W., Johnson D.A., Schmitt C, Collins D.W., Whipple J. et al. (2000): Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 14: 1249–1258.

    Article  PubMed  CAS  Google Scholar 

  • Kasper S., Müller-Spahn F. (2000): Review of quetiapine and its clinical applications in schizophrenia. Expert. Opin. Pharmacother. 1: 783–801.

    Article  PubMed  CAS  Google Scholar 

  • Kaufmann M., Bajetta E., Dirix L.Y., Fein L.E., Jones S.E., Zilembo N. et al. (2000): Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J. Clin. Oncol. 18:1399–1411.

    PubMed  CAS  Google Scholar 

  • King A.B. (2000): A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23: 557.

    Article  PubMed  CAS  Google Scholar 

  • Kinnell H.G. (2001): Bupropion for smokers. Drug is almost identical in structure to diethylpropion, a controlled drug. N. Engl. J. Med. 340: 431.

    Google Scholar 

  • Klitgaard H., Matagne A., Gobert J., Wulfert E. (2000): Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol.353:191–206.

    Article  Google Scholar 

  • Konecny G., Untch M., Pegram M. (1999): Herceptin in der Therapie des metasta-sierten Mammakarzinoms. Gynäkologe 32: 624–631.

    Google Scholar 

  • Krattenmacher R. (2000): Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62: 29–38.

    Article  PubMed  CAS  Google Scholar 

  • Kurtzhals P., Schäffer L., Sørensen A., Kristensen C., Jonassen L, Schmid C., Trüb T.(2000): Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999–1005.

    Article  PubMed  CAS  Google Scholar 

  • Kwan A.L., Meiners A.P., van Grootheest A.C., Lekkerkerker J.F. (2001): Risk of convulsions due to the use of bupropion as an aid for smoking cessation. Ned.Tijdschr. Geneeskd. 145: 277–278.

    PubMed  CAS  Google Scholar 

  • Lamb H.M., Figgitt D.P., Faulds D. (1999): Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58:1061–1097.

    Article  PubMed  CAS  Google Scholar 

  • Lanza F.L., Hunt R.H., Thomson A.B., Provenza J.M., Blank M.A. (2000a): Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119: 631–638.

    Article  PubMed  CAS  Google Scholar 

  • Lanza F., Schwartz H., Sahba B., Malaty H.M., Musliner T., Reyes R., Quan H., Graham D.Y. (2000b): An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am. J. Gastroenterol. 95: 3112–3117.

    Article  PubMed  CAS  Google Scholar 

  • Lemke A.J., Sander B., Balzer T., Geens V., Hosten N., Felix R. (1997): Sicherheit und Nutzen von Gadobutrol bei Patienten mit zerebralen Tumoren (Phase-III-Studie).Röfo. Fortschr. Geb. Röntgenstr. Neue Bildgeb. Verfahr. 167: 591–598.

    Article  CAS  Google Scholar 

  • Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J. et al.(2000): Etanercept in children with polyarticular juvenile rheumatoid arthritis.N. Engl. J. Med. 342: 763–769.

    Article  PubMed  CAS  Google Scholar 

  • Maestri N.E., Brusilow S.W., Clissold D.B., Bassett S.S. (1996): Long-term treatment of girls with ornithine transcarbamylase deficiency. N. Engl. J. Med. 335:855–859.

    Article  PubMed  CAS  Google Scholar 

  • Maul H., Winkler M., Rath W. (2000): Klinische Erfahrungen mit Atosiban. Neuer Oxytocin-Rezeptorantagonist zur Wehenhemmung. Dtsch. Ärztebl. 97: A3427–A3432.

    Google Scholar 

  • McClellan K.J., Jarvis B. (2000): Lercanidipine. A review of its use in hypertension.Drugs 60:1123–1140.

    Article  PubMed  CAS  Google Scholar 

  • McKee P.J., Blacklaw J., Forrest G., Gillham R.A., Walker S.M., Connelly D., Brodie M.J. (1994): A double-blind, placebo-controlled interaction study between ox-carbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br. J. Clin. Pharmacol. 37: 27–32.

    Article  PubMed  CAS  Google Scholar 

  • Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E. A., Fleischmann R.M., Bulpitt K.J. et al. (1999): Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. 130:478–486.

    PubMed  CAS  Google Scholar 

  • Noble S., Goa K.L. (2000): Amprenavir: a review of its clinical potential in patients with HIV infection. Drugs 60:1383–1410.

    Article  PubMed  CAS  Google Scholar 

  • Oelkers W., Heimerhorst F.M., Wuttke W., Heithecker R. (2000): Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol. Endocrinol. 14: 204–213.

    Article  PubMed  CAS  Google Scholar 

  • Parulkar A.A., Pendergrass M.L., Granda-Ayala R., Lee T.R., Fonseca V.A. (2001): Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 134: 61–71.

    PubMed  CAS  Google Scholar 

  • Peterson W.L., Cryer B. (1999): COX-1-sparing NSAIDs - is the enthusiasm justified? JAMA 282:1961–1963.

    Article  PubMed  CAS  Google Scholar 

  • Ravinuthala R.S., Nori U. (2000): Rosiglitazone toxicity. Ann. Intern. Med. 133: 658.

    PubMed  CAS  Google Scholar 

  • Reutter H., Bort S., Jung M.F., Klyscz T., Schippert W., Zuder D., Jünger M. (1999): Fragliche Wirksamkeit autologer thrombozytärer Wachstumsfaktoren (PDWHF) in der Behandlung venöser Beinulzera. Hautarzt 50: 859–865.

    Article  PubMed  CAS  Google Scholar 

  • Rush C.R., Kollins S.H., Pazzaglia P.J. (1998): Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-ampheta-mine-trained humans. Exp. Clin. Psychopharmacol. 6: 32–44.

    Article  PubMed  CAS  Google Scholar 

  • Sall K., the Brinzolamide Primary Therapy Study Group (2000): The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv. Ophthalmol. 44 (Suppl. 2): 163–168.

    Google Scholar 

  • Seymour H.E., Worsley A., Smith J.M., Thomas S.H.L. (2001): Anti-TNF agents for rheumatoid arthritis. Br. J. Clin. Pharmacol. 51: 201–208.

    Article  PubMed  CAS  Google Scholar 

  • Shiffman S., Johnston J.A., Khayrallah M., Elash C.A., Gwaltney C.J., Paty J.A. et al. (2000): The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148: 33–40.

    Article  PubMed  CAS  Google Scholar 

  • Simon L.S., Weaver A.L., Graham D.Y., Kivitz A.J., Lipsky P.E., Hubbard R.C. et al. (1999): Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial. JAMA 282:1921–1928.

    CAS  Google Scholar 

  • Smiell J.M., Wieman J., Steed D.L., Perry B.H., Sampson A.R., Schwab B.H. (1999): Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep. Reg. 7: 335–346.

    Article  CAS  Google Scholar 

  • Spencer C.M., Faulds D. (2000): Esomeprazole. Drugs 60: 321–329.

    Article  PubMed  CAS  Google Scholar 

  • Srisurapanont M., Disayavanish C., Taimkaew K. (2000): Quetiapine for schizophrenia. Cochrane Database Syst. Rev. 3: CD000967.

    PubMed  Google Scholar 

  • Staks T., Schuhmann-Giampieri G., Frenzel T., Weinmann H.J., Lange L., Platzek J. (1994): Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest. Radiol. 29: 709–715.

    Article  PubMed  CAS  Google Scholar 

  • TAP Study Group (1999): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch. Ophthalmol. 117: 1329–1345.

    Google Scholar 

  • TAP Study Group (2001): Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch. Ophthalmol. 119:198–207.

    Google Scholar 

  • The European and Middle East Orgalutran Study Group (2001): Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist troptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum. Reprod. 16: 644–651.

    Article  Google Scholar 

  • The Worldwide Atosiban versus Beta-agonists Study Group (2001): Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. BJOG 108:133–142.

    Article  Google Scholar 

  • Wiendl H., Neuhaus O., Kappos L., Hohlfeld R. (2000): Multiple Sklerose. Aktuelle Übersicht zu fehlgeschlagenen und abgebrochenen Therapiestudien. Nervenarzt 71: 597–610.

    Article  PubMed  CAS  Google Scholar 

  • Wolffenbuttel B.H., Gomis R., Squatrito S., Jones N.P., Patwardhan R.N. (2000): Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet. Med. 17:40–47.

    Article  PubMed  CAS  Google Scholar 

  • Yki-Järvinen H., Dresler A., Ziemen M., the HOE 901/3002 Study Group (2000): Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargin compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130–1136.

    Article  PubMed  Google Scholar 

  • Zung W.W. (1983): Review of placebo-controlled trials with bupropion. J. Clin. Psychiatry 44: 104–114.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Uwe Fricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Germany

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fricke, U., Schwabe, U. (2001). Neue Arzneimittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56434-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56434-5_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42079-8

  • Online ISBN: 978-3-642-56434-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation